ClinicalTrials.gg
Not yet recruitingNCT07567859Updated May 5, 2026

A Study of HS-10587 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-10587 in MTAP Deletion, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
362
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase I, multicenter, open-label clinical trial with dose escalation/dose expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HS-10587 in patients with MTAP-deleted advanced solid tumors.

02

Conditions studied

  • MTAP Deletion

Keywords

  • Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who voluntarily participate in this clinical study, understand the study procedures, and are able to sign a written ICF.
  2. Participants with locally advanced or recurrent malignant solid tumors confirmed by histopathology or cytopathology who have failed or are intolerant to at least one line of prior standard treatment, or for whom no standard treatment exists.
  3. Evidence of MTAP deletion in the tumor tissue.
  4. (ECOG) performance status of 0 or 1.
  5. ≥12 weeks.
  6. At least one that would qualify as target lesion by , Version 1.1 (RECIST 1.1).
  7. Female participants of are willing to take appropriate measures and should not breastfeed; male participants are willing to use barrier contraception.

Exclusion criteria

Exclusion Criteria:

  1. History of other primary .
  2. Presence of pleural/abdominal effusion or pericardial effusion requiring clinical intervention.
  3. Presence of , spinal cord compression, or brainstem ; known untreated , or symptomatic/unstable brain metastases.
  4. Participants who have any Grade ≥ 2 residual toxicity according to (CTCAE, version 6.0) from prior anti-tumor therapies (except alopecia, pigmentation, and residual neurotoxicity).
  5. Inadequate bone marrow reserve or hepatic and renal functions.
  6. Severe, uncontrolled, or active cardiovascular diseases.
  7. Severe or poorly controlled diabetes.
  8. Severe or poorly controlled hypertension.
  9. Severe infection within 4 weeks prior to the first dose.
  10. Long-term therapy, history of other acquired/congenital immunodeficiency disorders, or organ transplantation.
  11. Known active infectious diseases.
  12. gastrointestinal dysfunction.
  13. Moderate to severe pulmonary diseases that seriously affect respiratory function.
  14. Prior history of severe neurological or mental disorders.
  15. Female participants who are pregnant or breastfeeding, or plan to become pregnant during the study.
  16. History of severe allergies, or history of reactions to any active or inactive ingredients of HS-10587 or to drugs with similar chemical structures to HS-10587 or drugs of the same class as HS-10587.
  17. Participants with any conditions that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
362 participants (estimated)

Study arms

  • Experimental
    HS-10587 Monotherapy

    Dose escalation cohorts and dose expansion cohorts of varying doses of HS-10587

    Drug: HS-10587

Interventions

  • DrugHS-10587

    HS-10587 tablet

06

What researchers measure

Primary outcomes

  1. Incidence of DLT

    dose-limiting toxicities

    Time frame: Up to 21 days after the first administration. (first cycle)

  2. MTD or MAD

    maximum tolerated dose (MTD) or maximum applicable dose (MAD)

    Time frame: Up to 21 days after the first administration. (first cycle)

Secondary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with AEs and SAEs

    Time frame: From time of informed consent to 28 days post last dose of HS-10587.

  2. Pharmacokinetics (PK) profile of HS-10587 in patients with advanced solid tumors

    Maximum concentration (Cmax).

    Time frame: Predose and postdose up to end of treatment, approximately 2 years

  3. Pharmacokinetics (PK) profile of HS-10587 in patients with advanced solid tumors

    Time of maximum concentration (Tmax).

    Time frame: Predose and postdose up to end of treatment, approximately 2 years.

  4. Pharmacokinetics (PK) profile of HS-10587 in patients with advanced solid tumors

    area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration (AUC0-t)

    Time frame: Predose and postdose up to end of treatment, approximately 2 years.

  5. Pharmacokinetics (PK) profile of HS-10587 in patients with advanced solid tumors

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)

    Time frame: Predose and postdose up to end of treatment, approximately 2 years

  6. Efficacy of HS-10587 in patients with advanced solid tumors

    Objective response rate (ORR) evaluated as per RECIST v1.1

    Time frame: Predose and post dose up to end of treatment, approximately 2 years

  7. Efficacy of HS-10587 in patients with advanced solid tumors.

    Duration of response (DOR) evaluated as per RECIST v1.1

    Time frame: Predose and post dose up to end of treatment, approximately 2 years.

  8. Efficacy of HS-10587 in patients with advanced solid tumors.

    Disease control rate (DCR) evaluated as per RECIST v1.1

    Time frame: Predose and post dose up to end of treatment, approximately 2 years

  9. Efficacy of HS-10587 in patients with advanced solid tumors.

    Time to response (TTR) evaluated as per RECIST v1.1

    Time frame: Predose and post dose up to end of treatment, approximately 2 years.

  10. Efficacy of HS-10587 in patients with advanced solid tumors.

    Progression-free survival (PFS) evaluated as per RECIST v1.1

    Time frame: Predose and post dose up to end of treatment, approximately 2 years.

  11. Efficacy of HS-10587 in patients with advanced solid tumors.

    Overall survival (OS) evaluated as per RECIST v1.1

    Time frame: Predose and post dose up to end of treatment, approximately 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 5, 2026
StartEst.
Jun 4, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07567859
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Jun 4, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion